Works matching DE "BLOOD coagulation factor IX"
Results: 588
Andexanet alfa for oral fxa inhibitor-associated major acute intracerebral hemorrhage: insights into clinically relevant thromboembolic events from the ANNEXA-I study.
- Published in:
- Jornal Vascular Brasileiro, 2024, v. 23, p. 1, doi. 10.1590/1677-5449.202401332
- By:
- Publication type:
- Article
Phosphatidylserine Regulation of Coagulation Proteins Factor IXa and Factor VIIIa.
- Published in:
- 2022
- By:
- Publication type:
- journal article
An unusual swelling of the fingers.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Biosensing human blood clotting factor by dual probes: Evaluation by deep long short‐term memory networks in time series forecasting.
- Published in:
- Biotechnology & Applied Biochemistry, 2022, v. 69, n. 3, p. 930, doi. 10.1002/bab.2164
- By:
- Publication type:
- Article
PERFIL CLÍNICO-EPIDEMIOLÓGICO DAS HEMOFILIAS A E B NO ESTADO DO MARANHÃO.
- Published in:
- Revista Foco (Interdisciplinary Studies Journal), 2023, v. 16, n. 12, p. 1, doi. 10.54751/revistafoco.v16n12-087
- By:
- Publication type:
- Article
Comprehensive Comparison of AAV Purification Methods: Iodixanol Gradient Centrifugation vs. Immuno-Affinity Chromatography.
- Published in:
- Advances in Cell & Gene Therapy, 2023, p. 1, doi. 10.1155/2023/2339702
- By:
- Publication type:
- Article
Epigenetic modification mechanism of histone demethylase KDM1A in regulating cardiomyocyte apoptosis after myocardial ischemia-reperfusion injury.
- Published in:
- PeerJ, 2022, p. 1, doi. 10.7717/peerj.13823
- By:
- Publication type:
- Article
Investigation on the binding mode of benzothiophene analogues as potent factor IXa (FIXa) inhibitors in thrombosis by CoMFA, docking and molecular dynamic studies.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2011, v. 26, n. 6, p. 792, doi. 10.3109/14756366.2011.554414
- By:
- Publication type:
- Article
Population Inversion of Ar VIII Levels in the Plasma of Fast Conical Discharge.
- Published in:
- Journal of Experimental & Theoretical Physics, 2022, v. 135, n. 3, p. 383, doi. 10.1134/S1063776122090011
- By:
- Publication type:
- Article
Fc-fusion proteins: therapeutic relevance and quality assessment.
- Published in:
- Macedonian Pharmaceutical Bulletin / Makedonsko Farmacevtski Bilten, 2022, v. 68, p. 65, doi. 10.33320/maced.pharm.bull.2022.68.03.028
- By:
- Publication type:
- Article
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-70784-x
- By:
- Publication type:
- Article
Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives.
- Published in:
- Biomolecules (2218-273X), 2024, v. 14, n. 7, p. 854, doi. 10.3390/biom14070854
- By:
- Publication type:
- Article
The Interaction of Factor Xa and IXa with Non-Activated Antithrombin in Michaelis Complex: Insights from Enhanced-Sampling Molecular Dynamics Simulations.
- Published in:
- Biomolecules (2218-273X), 2023, v. 13, n. 5, p. 795, doi. 10.3390/biom13050795
- By:
- Publication type:
- Article
Caracterización clinicoepidemiológica de pacientes con hemofilia congénita de tipos A y B en Santiago de Cuba.
- Published in:
- MEDISAN, 2022, v. 26, n. 3, p. 54
- By:
- Publication type:
- Article
Voices of patients with hemophilia: Life‐changing gene therapy.
- Published in:
- Haemophilia, 2024, v. 30, n. 6, p. 1444, doi. 10.1111/hae.15104
- By:
- Publication type:
- Article
We need better health‐related quality‐of‐life data for children with haemophilia in lower‐income countries.
- Published in:
- Haemophilia, 2024, v. 30, n. 6, p. 1429, doi. 10.1111/hae.15095
- By:
- Publication type:
- Article
Real‐world experience of rIX‐FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy – Results from IDEAL Part B.
- Published in:
- Haemophilia, 2024, v. 30, n. 4, p. 1067, doi. 10.1111/hae.15074
- By:
- Publication type:
- Article
Identifying hemophilia B carriers: Utility of aPTT, factor IX levels and ratios of factor IX to other Vitamin K dependent factors.
- Published in:
- Haemophilia, 2024, v. 30, n. 4, p. 1003, doi. 10.1111/hae.15068
- By:
- Publication type:
- Article
Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi‐country severe WAPPS‐Hemo haemophilia patients.
- Published in:
- Haemophilia, 2024, v. 30, n. 4, p. 925, doi. 10.1111/hae.15032
- By:
- Publication type:
- Article
Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS‐Hemo platform.
- Published in:
- Haemophilia, 2024, v. 30, n. 4, p. 988, doi. 10.1111/hae.15027
- By:
- Publication type:
- Article
Origin of pathogenic variant and mosaicism in families with a sporadic case of haemophilia B.
- Published in:
- Haemophilia, 2024, v. 30, n. 3, p. 774, doi. 10.1111/hae.15019
- By:
- Publication type:
- Article
Haemophilia care in Asia: Learning from clinical practice in some Asian countries.
- Published in:
- Haemophilia, 2024, v. 30, n. 3, p. 609, doi. 10.1111/hae.14998
- By:
- Publication type:
- Article
EAHAD haemophilia gene therapy clinical outcome database (EAHAD‐GTD).
- Published in:
- Haemophilia, 2024, v. 30, n. 3, p. 852, doi. 10.1111/hae.14981
- By:
- Publication type:
- Article
Genetic variant detection in a South African haemophilia B population.
- Published in:
- Haemophilia, 2024, v. 30, n. 3, p. 765, doi. 10.1111/hae.14978
- By:
- Publication type:
- Article
Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy.
- Published in:
- Haemophilia, 2024, v. 30, n. 3, p. 709, doi. 10.1111/hae.14977
- By:
- Publication type:
- Article
Haemophilia in the era of novel therapies: Where do inhibitors feature in the new landscape?
- Published in:
- Haemophilia, 2024, v. 30, p. 95, doi. 10.1111/hae.14982
- By:
- Publication type:
- Article
Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective.
- Published in:
- Haemophilia, 2024, v. 30, n. 2, p. 257, doi. 10.1111/hae.14944
- By:
- Publication type:
- Article
Emicizumab and asparaginase, A first experience to share.
- Published in:
- Haemophilia, 2024, v. 30, n. 2, p. 561, doi. 10.1111/hae.14935
- By:
- Publication type:
- Article
Gene therapy for haemophilia A and B, from basic principles to clinical implementation: An illustrated review.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 5, doi. 10.1111/hae.14907
- By:
- Publication type:
- Article
Observational cohort study of long‐term outcomes of liver transplantation in haemophilia.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 87, doi. 10.1111/hae.14910
- By:
- Publication type:
- Article
Health‐related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study).
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 98, doi. 10.1111/hae.14899
- By:
- Publication type:
- Article
Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 75, doi. 10.1111/hae.14882
- By:
- Publication type:
- Article
A next generation FVIII mimetic bispecific antibody, Mim8, the impact on non‐factor VIII related haemostasis assays.
- Published in:
- Haemophilia, 2023, v. 29, n. 6, p. 1633, doi. 10.1111/hae.14884
- By:
- Publication type:
- Article
Characterization of a recombinant factor IX molecule fused to coagulation factor XIII‐B subunit.
- Published in:
- Haemophilia, 2023, v. 29, n. 6, p. 1483, doi. 10.1111/hae.14855
- By:
- Publication type:
- Article
Evaluation of treatment and outcome for patients with haemophilia A and haemophilia B on extended half‐life (EHL) factor products: A 12‐month data analysis.
- Published in:
- Haemophilia, 2023, v. 29, n. 5, p. 1283, doi. 10.1111/hae.14842
- By:
- Publication type:
- Article
Development of inhibitors in women with mild haemophilia A and concurrent treatment with immune tolerance therapy and emicizumab.
- Published in:
- Haemophilia, 2023, v. 29, n. 4, p. 1167, doi. 10.1111/hae.14821
- By:
- Publication type:
- Article
Towards achieving a haemophilia‐free mind.
- Published in:
- Haemophilia, 2023, v. 29, n. 4, p. 951, doi. 10.1111/hae.14807
- By:
- Publication type:
- Article
No difference in quality of life between persons with severe haemophilia A and B.
- Published in:
- Haemophilia, 2023, v. 29, n. 4, p. 987, doi. 10.1111/hae.14759
- By:
- Publication type:
- Article
Advancing haemophilia care in Pakistan: Progress and future directions.
- Published in:
- Haemophilia, 2023, v. 29, n. 3, p. 939, doi. 10.1111/hae.14789
- By:
- Publication type:
- Article
SPEAKER ABSTRACTS.
- Published in:
- Haemophilia, 2023, v. 29, p. 5, doi. 10.1111/hae.14713
- Publication type:
- Article
Primary prophylaxis in children with severe haemophilia A and B—Implementation over the last 20 years as illustrated in real‐world data in the PedNet cohorts.
- Published in:
- Haemophilia, 2023, v. 29, n. 2, p. 498, doi. 10.1111/hae.14729
- By:
- Publication type:
- Article
Plasma‐derived factor VIIa and factor X mixture agent (MC710) prophylaxis in haemophilia B patients with inhibitors.
- Published in:
- Haemophilia, 2023, v. 29, n. 2, p. 456, doi. 10.1111/hae.14710
- By:
- Publication type:
- Article
POSTER ABSTRACTS.
- Published in:
- Haemophilia, 2023, v. 29, p. 24, doi. 10.1111/hae.14715
- By:
- Publication type:
- Article
Pharmacokinetic parameters of recombinant factor IX Fc fusion protein are not influenced by factor IX antigen levels in subjects from the Phase 3 B‐LONG trial.
- Published in:
- Haemophilia, 2023, v. 29, n. 1, p. 404, doi. 10.1111/hae.14727
- By:
- Publication type:
- Article
Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors.
- Published in:
- Haemophilia, 2023, v. 29, n. 1, p. 348, doi. 10.1111/hae.14685
- By:
- Publication type:
- Article
Real‐world prophylactic usage of recombinant factor IX Fc in Sweden: A report from the Swedish National Registry for bleeding disorders.
- Published in:
- Haemophilia, 2023, v. 29, n. 1, p. 377, doi. 10.1111/hae.14704
- By:
- Publication type:
- Article
Emicizumab assays evaluations with four different reagents in severe haemophilia A patients: Concentration from baseline to maintenance therapy.
- Published in:
- Haemophilia, 2023, v. 29, n. 1, p. 374, doi. 10.1111/hae.14703
- By:
- Publication type:
- Article
Haemophilia A and B – evaluation of the Swedish prophylactic regimen by magnetic resonance imaging.
- Published in:
- Haemophilia, 2023, v. 29, n. 1, p. 193, doi. 10.1111/hae.14693
- By:
- Publication type:
- Article
IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy.
- Published in:
- Haemophilia, 2023, v. 29, n. 1, p. 135, doi. 10.1111/hae.14689
- By:
- Publication type:
- Article
Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China.
- Published in:
- Haemophilia, 2023, v. 29, n. 1, p. 123, doi. 10.1111/hae.14665
- By:
- Publication type:
- Article